Bristol’s Next CEO Is Caforio, Tasked With Leading Immuno-Oncology Charge
This article was originally published in The Pink Sheet Daily
Bristol CEO Lamberto Andreotti will step down as CEO in May but remain as chairman of the board, making way for insider Giovanni Caforio to take over the top slot. His task will be overseeing Bristol’s transition to a commercial-stage immuno-oncology powerhouse.
You may also be interested in...
Opdivo sales got out of the gate slowly, but Bristol sees encouraging trends – and has a validated diagnostic for the PD-L1 therapy at the ready, if needed.
Now that the PD-1 inhibitor has a melanoma approval under its belt, Bristol-Myers is moving full steam ahead with the development of Opdivo with 11 lung cancer clinical trials ongoing or planned.
As Sanofi looks for a replacement for Chris Viehbacher, it might want to take the recent track records of the CEOs at its competitors into consideration before making a decision.